Pathogenesis and treatment of chronic kidney disease: A review of our recent basic and clinical data

Kidney and Blood Pressure Research

Volumn 39, Issue 5, 2014, Pages 450-489

  Tomino, Yasuhiko ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

Diabetic nephropathy; Hemodialysis; IgA nephropathy; Peritoneal dialysis; Ultrasonography

Indexed keywords

5 ETHOXYMETHOXY N HYDROXY 2 METHYL 4 (4 PHENOXYBENZAMIDO)PENTANAMIDE; ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSIN[1-7]; BENIDIPINE; CHEMOKINE; CHLORHEXIDINE GLUCONATE; COLLAGEN TYPE 4; CYSTATIN C; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN A; IMMUNOSUPPRESSIVE AGENT; LIPOSOME; MONOCLONAL ANTIBODY; OLMESARTAN; PREDNISOLONE; STEROID; TUMOR NECROSIS FACTOR RECEPTOR; VITAMIN D DERIVATIVE;

ALBUMINURIA; BLOOD CHEMISTRY; BONE MARROW TRANSPLANTATION; CELL DAMAGE; CELL INFILTRATION; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; COMPLEMENT ACTIVATION; DIABETIC NEPHROPATHY; DISEASE COURSE; ECHOCARDIOGRAPHY; EXERCISE; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HISTOPATHOLOGY; HOSPITALIZATION; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; INTERSTITIUM; KIDNEY BIOPSY; MAST CELL; MUCOSAL IMMUNITY; NONHUMAN; PATHOGENESIS; PATIENT CARE; PATIENT EDUCATION; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PODOCYTE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN INTAKE; PRURITUS; RENAL REPLACEMENT THERAPY; REVIEW; SALT INTAKE; TONSILLECTOMY; URINALYSIS; ANIMAL; CLINICAL TRIAL (TOPIC); DISEASE MODEL; GLOMERULONEPHRITIS; GLOMERULONEPHRITIS, IGA; METABOLISM; MOUSE; PROCEDURES; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GLOMERULONEPHRITIS; GLOMERULONEPHRITIS, IGA; HUMANS; MICE; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84917691413     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000368458     Document Type: Review

References (144)

1. Berger J, Hinglais N: Intercapillary deposits of IgA-IgG. J Urol Nephrol (Paris) 1968;74:694-695
2. Nakayama K, Ohsawa I, Maeda-Ohtani A, Murakoshi M, Horikoshi S, Tomino Y: Prediction of diagnosis of immunoglobulin A nephropathy prior to renal biopsy and correlation with urinary sediment findings and prognostic grading. J Clin Lab Anal 2008;22:114-118
3. Working Group of the International Ig ANN, the Renal Pathology S, Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D'Agati V, D'Amico G, Emancipator S, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Leung CB, Li LS, Li PK, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H: The Oxford classification of IgA nephropathy: Rationale, clinicopathological correlations, and classification. Kidney Int 2009;76:534-545
4. Kawamura T, Joh K, Okonogi H, Koike K, Utsunomiya Y, Miyazaki Y, Matsushima M, Yoshimura M, Horikoshi S, Suzuki Y, Furusu A, Yasuda T, Shirai S, Shibata T, Endoh M, Hattori M, Katafuchi R, Hashiguchi A, Kimura K, Matsuo S, Tomino Y, Study Group Special Ig AN: A histologic classification of IgA nephropathy for predicting long-term prognosis: Emphasis on end-stage renal disease. J Nephrol 2013;26:350-357
5. Roos A, Rastaldi MP, Calvaresi N, Oortwijn BD, Schlagwein N, van Gijlswijk-Janssen DJ, Stahl GL, Matsushita M, Fujita T, van Kooten C, Daha MR: Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol 2006;17:1724-1734
6. Onda K, Ohi H, Tamano M, Ohsawa I, Wakabayashi M, Horikoshi S, Fujita T, Tomino Y: Hypercomplementemia in adult patients with IgA nephropathy. J Clin Lab Anal 2007;21:77-84
7. Suzuki H, Ohsawa I, Kodama F, Nakayama K, Ohtani A, Onda K, Nagamachi S, Kurusu A, Suzuki Y, Ohi H, Horikoshi S, Tomino Y: Fluctuation of serum C3 levels reflects disease activity and metabolic background in patients with IgA nephropathy. J Nephrol 2013;26:708-715
8. Shimamoto M, Ohsawa I, Suzuki H, Hisada A, Nagamachi S, Honda D, Inoshita H, Shimizu Y, Horikoshi S, Tomino Y: Impact of body mass index on progression of IgA nephropathy among Japanese patients. J Clin Lab Anal 2014, DOI 10.1002/jcla.21778
9. Ohsawa I, Kusaba G, Ishii M, Sato N, Inoshita H, Onda K, Hashimoto A, Nagamachi S, Suzuki H, Shimamoto M, Ohi H, Horikoshi S, Tomino Y: Extraglomerular C3 deposition and metabolic impacts in patients with IgA nephropathy. Nephrol Dial Transplant 2013;28:1856-1864
10. Kusaba G, Ohsawa I, Ishii M, Inoshita H, Takagi M, Tanifuji C, Takahashi K, Nakamoto J, Yoshida M, Ohi H, Horikoshi S, Kurihara H, Tomino Y: Significance of broad distribution of electron-dense deposits in patients with IgA nephropathy. Med Mol Morphol 2012;45:29-34
11. Lemley KV, Lafayette RA, Safai M, Derby G, Blouch K, Squarer A, Myers BD: Podocytopenia and disease severity in IgA nephropathy. Kidney Int 2002;61:1475-1485
12. Hishiki T, Shirato I, Takahashi Y, Funabiki K, Horikoshi S, Tomino Y: Podocyte injury predicts prognosis in patients with IgA nephropathy using a small amount of renal biopsy tissue. Kidney Blood Press Res 2001;24:99-104
13. Kodama F, Asanuma K, Takagi M, Hidaka T, Asanuma E, Fukuda H, Seki T, Takeda Y, Hosoe-Nagai Y, Asao R, Horikoshi S, Tomino Y: Translocation of dendrin to the podocyte nucleus in acute glomerular injury in patients with IgA nephropathy. Nephrol Dial Transplant 2013;28:1762-1772
14. Sakamoto-Ihara T, Suzuki Y, Kurusu A, Yamashita M, Horikoshi S, Tomino Y: Possible involvement of mast cells in renal fibrosis in patients with IgA nephropathy. Inflamm Res 2007;56:421-427
15. Imai H, Nakamoto Y, Asakura K, Miki K, Yasuda T, Miura AB: Spontaneous glomerular IgA deposition in ddY mice: An animal model of IgA nephritis. Kidney Int 1985;27:756-761
16. Suzuki H, Suzuki Y, Yamanaka T, Hirose S, Nishimura H, Toei J, Horikoshi S, Tomino Y: Genome-wide scan in a novel IgA nephropathy model identifies a susceptibility locus on murine chromosome 10, in a region syntenic to human IGAN1 on chromosome 6q22-23. J Am Soc Nephrol 2005;16:1289-1299
17. Gharavi AG, Yan Y, Scolari F, Schena FP, Frasca GM, Ghiggeri GM, Cooper K, Amoroso A, Viola BF, Battini G, Caridi G, Canova C, Farhi A, Subramanian V, Nelson-Williams C, Woodford S, Julian BA, Wyatt RJ, Lifton RP: IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet 2000;26:354-357
18. Liao J, Hayashi K, Horikoshi S, Ushijima H, Kimura J, Tomino Y: Effect of steroid-liposome on immunohistopathology of IgA nephropathy in ddY mice. Nephron 2001;89:194-200
19. Shimizu M, Shou I, Tsuge T, Abe M, Tomino Y: Effect of mizoribine on glomerulonephritis of early-stage IgA nephropathy in ddY mice. Nephron 1998;79:67-72
20. Tomino Y, Shimizu M, Koide H, Abe M, Shirai T: Effect of monoclonal antibody CD4 on glomerulonephritis of ddY mice, a spontaneous animal model of IgA nephropathy. Am J Kidney Dis 1993;21:427-432
21. Sakai O: IgA nephropathy: Current concepts and future trends. Nephrology 1997;3:2-3
22. Imasawa T, Nagasawa R, Utsunomiya Y, Kawamura T, Zhong Y, Makita N, Muso E, Miyawaki S, Maruyama N, Hosoya T, Sakai O, Ohno T: Bone marrow transplantation attenuates murine IgA nephropathy: Role of a stem cell disorder. Kidney Int 1999;56:1809-1817
23. Suzuki H, Suzuki Y, Aizawa M, Yamanaka T, Kihara M, Pang H, Horikoshi S, Tomino Y: Th1 polarization in murine IgA nephropathy directed by bone marrow-derived cells. Kidney Int 2007;72:319-327
24. Bonner A, Furtado PB, Almogren A, Kerr MA, Perkins SJ: Implications of the near-planar solution structure of human myeloma dimeric IgA1 for mucosal immunity and IgA nephropathy. J Immunol 2008;180:1008-1018
25. Kokubo T, Hiki Y, Iwase H, Tanaka A, Toma K, Hotta K, Kobayashi Y: Protective role of IgA1 glycans against IgA1 self-Aggregation and adhesion to extracellular matrix proteins. J Am Soc Nephrol 1998;9:2048-2054
26. Yan Y, Xu LX, Zhang JJ, Zhang Y, Zhao MH: Self-Aggregated deglycosylated IgA1 with or without IgG were associated with the development of IgA nephropathy. Clin Exp Immunol 2006;144:17-24
27. Oortwijn BD, van der Boog PJ, Roos A, van der Geest RN, de Fijter JW, Daha MR, van Kooten C: A pathogenic role for secretory IgA in IgA nephropathy. Kidney Int 2006;69:1131-1138
28. Suzuki H, Suzuki Y, Narita I, Aizawa M, Kihara M, Yamanaka T, Kanou T, Tsukaguchi H, Novak J, Horikoshi S, Tomino Y: Toll-like receptor 9 affects severity of IgA nephropathy. J Am Soc Nephrol 2008;19:2384-2395
29. Tomino Y, Ohmuro H, Kuramoto T, Shirato I, Eguchi K, Sakai H, Okumura K, Koide H: Expression of intercellular adhesion molecule-1 and infiltration of lymphocytes in glomeruli of patients with IgA nephropathy. Nephron 1994;67:302-307
30. Maeda A, Gohda T, Funabiki K, Horikoshi S, Shirato I, Tomino Y: Significance of serum IgA levels and serum IgA/C3 ratio in diagnostic analysis of patients with IgA nephropathy. J Clin Lab Anal 2003;17:73-76
31. Saitoh A, Suzuki Y, Takeda M, Kubota K, Itoh K, Tomino Y: Urinary levels of monocyte chemoattractant protein (MCP)-1 and disease activity in patients with IgA nephropathy. J Clin Lab Anal 1998;12:1-5
32. Tomino Y, Funabiki K, Ohmuro H, Shimizu M, Yokoyama K, Shirato I, Shirai T, Takahashi M, Koide H: Urinary levels of interleukin-6 and disease activity in patients with IgA nephropathy. Am J Nephrol 1991;11:459-464
33. Yanagawa H, Suzuki H, Suzuki Y, Kiryluk K, Gharavi AG, Matsuoka K, Makita Y, Julian BA, Novak J, Tomino Y: A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases. PLoS One 2014;9:e98081
34. Yamaji K, Kurusu A, Okamoto M, Sekiguchi Y, Horikoshi S, Tomino Y: Effect of educational hospitalization on chronic kidney disease (CKD) patients. Clin Nephrol 2007;68:401-404
35. Kobayashi T, Yamaji K, Takeda Y, Maiguma M, Omote K, Sekiguchi Y, Tsuge T, Shimizu Y, Suzuki Y, Ohsawa I, Kurusu A, Hamada C, Horikoshi S, Tomino Y: Efficacy of educational short-term hospitalization in patients with chronic kidney disease (CKD): Second report. . Nephrol Frontier (Jap) 2011;10:94-98
36. Tomino Y, Kawamura T, Kimura K, Endoh M, Hosoya T, Horikoshi S, Utsunomiya Y, Yasuda T, Toyoda M, Tsuge T, Kaneko K: Antiproteinuric effect of olmesartan in patients with IgA nephropathy. J Nephrol 2009;22:224-231
37. Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T: Ca2+ channel subtypes and pharmacology in the kidney. Circ Res 2007;100:342-353
38. Takenaka T, Takane H, Okada H, Ohno Y, Suzuki H: Long-term effects of calcium antagonists on augmentation index in hypertensive patients with chronic kidney diseases. NDT Plus 2009;2:192-193
39. Tomino Y, Shimizu Y, Hamada C, Kurusu A, Ohsawa I, Suzuki Y, Tsuge T, Io H, Kobayashi N, Takeda Y, Asanuma K, Tanaka Y, Suzuki H, Nakata J, Takara K, Horikoshi S: One-year results of an open-label study on antiproteinuric effect of benidipine in elderly patients with chronic kidney disease. J Nephrol 2011;24:756-763
40. Kobayashi Y, Hiki Y, Kokubo T, Horii A, Tateno S: Steroid therapy during the early stage of progressive IgA nephropathy. A 10-year follow-up study. Nephron 1996;72:237-242
41. Tomino Y, Suzuki H, Horikoshi S, Imai E, Miyazaki M, Ohzono Y, Harada T, Yoshida H, Kawamura T, Kobayashi Y, Suzuki S, Nitta K, Hotta O, Yoshikwa N, Endoh M, Sakai H: Multicenter trial of adrenocorticosteroids in Japanese patients with IgA nephropathy- results of the special study group ( IgA nephropathy) on progressive glomerular disease, Ministry of Health, Labor and Welfare of Japan. Curr Topics Steroid Res 2004;4:93-98
42. Hotta O, Miyazaki M, Furuta T, Tomioka S, Chiba S, Horigome I, Abe K, Taguma Y: Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis 2001;38:736-743
43. Miura N, Imai H, Kikuchi S, Hayashi S, Endoh M, Kawamura T, Tomino Y, Moriwaki K, Kiyomoto H, Kohagura K, Nakazawa E, Kusano E, Mochizuki T, Nomura S, Sasaki T, Kashihara N, Soma J, Tomo T, Nakabayashi I, Yoshida M, Watanabe T: Tonsillectomy and steroid pulse (TSP) therapy for patients with IgA nephropathy: A nationwide survey of TSP therapy in Japan and an analysis of the predictive factors for resistance to TSP therapy. Clin Exp Nephrol 2009;13:460-466
44. Sato D, Suzuki Y, Kano T, Suzuki H, Matsuoka J, Yokoi H, Horikoshi S, Ikeda K, Tomino Y: Tonsillar TLR9 expression and efficacy of tonsillectomy with steroid pulse therapy in IgA nephropathy patients. Nephrol Dial Transplant 2012;27:1090-1097
45. Kawamura T, Yoshimura M, Miyazaki Y, Okamoto H, Kimura K, Hirano K, Matsushima M, Utsunomiya Y, Ogura M, Yokoo T, Okonogi H, Ishii T, Hamaguchi A, Ueda H, Furusu A, Horikoshi S, Suzuki Y, Shibata T, Yasuda T, Shirai S, Imasawa T, Kanozawa K, Wada A, Yamaji I, Miura N, Imai H, Kasai K, Soma J, Fujimoto S, Matsuo S, Tomino Y, Special Ig ANSG: A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Nephrol Dial Transplant 2014;29:1546-1553
46. Nakata J, Suzuki Y, Suzuki H, Sato D, Kano T, Yanagawa H, Matsuzaki K, Horikoshi S, Novak J, Tomino Y: Changes in nephritogenic serum galactose-deficient IgA1 in IgA nephropathy following tonsillectomy and steroid therapy. PLoS One 2014;9:e89707
47. Suzuki Y, Matsuzaki K, Suzuki H, Sakamoto N, Joh K, Kawamura T, Tomino Y, Matsuo S: Proposal of remission criteria for IgA nephropathy. Clin Exp Nephrol 2014;18:481-486
48. Koyama A, Igarashi M, Kobayashi M: Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases. Am J Kidney Dis 1997;29:526-532
49. Goto M, Wakai K, Kawamura T, Ando M, Endoh M, Tomino Y: A scoring system to predict renal outcome in IgA nephropathy: A nationwide 10-year prospective cohort study. Nephrol Dial Transplant 2009;24:3068-3074
50. Gohda T, Tomino Y: A paradigm shift for the concept of diabetic nephropathy. Juntendo Med J 2014, in press. 51 Araki S: APOE polymorphism and diabetic nephropathy. Clin Exp Nephrol 2014;18:230-233
51. Horikoshi S, Higurashi A, Kaneko E, Yoshimura H, Ohsawa I, Suzuki Y, Hamada C, Tomino Y: A new screening method for proteinuria using Erythrosin B and an automated analyzer-rapid, sensitive and inexpensive determination. Clin Chim Acta 2012;413:1087-1091
52. Horikoshi S, Okuda M, Nishimura E, Ohsawa I, Suzuki Y, Shimizu Y, Hamada C, Tomino Y: Usefulness of HPLC assay for early detection of microalbuminuria in chronic kidney disease. J Clin Lab Anal 2013;27:333-338
53. Iijima T, Suzuki S, Sekizuka K, Hishiki T, Yagame M, Jinde K, Saotome N, Suzuki D, Sakai H, Tomino Y: Followup study on urinary type IV collagen in patients with early stage diabetic nephropathy. J Clin Lab Anal 1998;12:378-382
54. Tomino Y, Suzuki S, Azushima C, Shou I, Iijima T, Yagame M, Wang LN, Chen HC, Lai KN, Tan SY, Kim MJ: Asian multicenter trials on urinary type IV collagen in patients with diabetic nephropathy. J Clin Lab Anal 2001;15:188-192
55. Tashiro K, Koyanagi I, Saitoh A, Shimizu A, Shike T, Ishiguro C, Koizumi M, Funabiki K, Horikoshi S, Shirato I, Tomino Y: Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy. J Clin Lab Anal 2002;16:1-4
56. Murakoshi M, Gohda T, Tanimoto M, Funabiki K, Horikoshi S, Tomino Y: Role of mindin in diabetic nephropathy. Exp Diabetes Res 2011;2011:486305
57. Murakoshi M, Tanimoto M, Gohda T, Hagiwara S, Takagi M, Horikoshi S, Tomino Y: Mindin: A novel marker for podocyte injury in diabetic nephropathy. Nephrol Dial Transplant 2011;26:2153-2160
58. Barrett AJ, Davies ME, Grubb A: The place of human gamma-trace (cystatin C) amongst the cysteine proteinase inhibitors. Biochem Biophys Res Commun 1984;120:631-636
59. Shimizu-Tokiwa A, Kobata M, Io H, Kobayashi N, Shou I, Funabiki K, Fukui M, Horikoshi S, Shirato I, Saito K, Tomino Y: Serum cystatin C is a more sensitive marker of glomerular function than serum creatinine. Nephron 2002;92:224-226
60. Tomino Y, Suzuki S, Gohda T, Kobayashi M, Horikoshi S, Imai H, Saito T, Kawamura T, Yorioka N, Harada T, Yasumoto Y, Kida H, Kobayashi Y, Endoh M, Sato H, Saito K: Serum cystatin C may predict the prognostic stages of patients with IgA nephropathy prior to renal biopsy. J Clin Lab Anal 2001;15:25-29
61. Shimizu A, Horikoshi S, Rinnno H, Kobata M, Saito K, Tomino Y: Serum cystatin C may predict the early prognostic stages of patients with type 2 diabetic nephropathy. J Clin Lab Anal 2003;17:164-167
62. Locksley RM, Killeen N, Lenardo MJ: The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 2001;104:487-501
63. Gohda T, Tomino Y: Novel biomarkers for the progression of diabetic nephropathy: Soluble TNF receptors. Curr Diab Rep 2013;13:560-566
64. Omote K, Gohda T, Murakoshi M, Sasaki Y, Kazuno S, Fujimura T, Ishizaka M, Sonoda Y, Tomino Y: Role of the TNF pathway in the progression of diabetic nephropathy in KK-A(y) mice. Am J Physiol Renal Physiol 2014;306:F1335-1347
65. Friedman EA: Advanced glycation end-products in diabetic nephropathy. Nephrol Dial Transplant 1999;14:1-9
66. Niewczas MA, Gohda T, Skupien J, Smiles AM, Walker WH, Rosetti F, Cullere X, Eckfeldt JH, Doria A, Mayadas TN, Warram JH, Krolewski AS: Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol 2012;23:507-515
67. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M: Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 1994;91:11704-11708
68. Suzuki D, Miyata T, Kurokawa K: Carbonyl stress. Contrib Nephrol 2001;36-45
69. Yamagishi S, Takeuchi M, Makita Z: Advanced glycation end products and the pathogenesis of diabetic nephropathy. Contrib Nephrol 2001;30-35
70. Shou I, Fukui M, Tomino Y: Efficacy of ACE inhibitor (captopril) on glomerular antioxidant enzyme activity and hypertension in diabetic hypertensive rats. Contrib Nephrol 2001;74-78
71. Tanaka M, Suzuki Y, Shirato I, Takahara H, Shibata T, Sugaya T, Shimamoto K, Horikoshi S, Tomino Y: Tubular epithelial cells have the capacity to transdifferentiate into CD68-positive macrophage-like cells by oxidative stress. Inflamm Res 2008;57:593-600
72. Jenkins AJ, Lyons TJ, Zheng D, Otvos JD, Lackland DT, McGee D, Garvey WT, Klein RL, Group DER: Lipoproteins in the DCCT/EDIC cohort: Associations with diabetic nephropathy. Kidney Int 2003;64:817-828
73. Toyama T, Shimizu M, Furuichi K, Kaneko S, Wada T: Treatment and impact of dyslipidemia in diabetic nephropathy. Clin Exp Nephrol 2014;18:201-205
74. Kondo K, Nozawa K, Tomita T, Ezaki K: Inbred strains resulting from Japanese Mice. Bull Exp Animal 1957;6:107-112
75. Nishimura M: Breeding of mice strains for diabetes mellitus. Exp Animal 1969;18:147-157
76. Ito T, Tanimoto M, Yamada K, Kaneko S, Matsumoto M, Obayashi K, Hagiwara S, Murakoshi M, Aoki T, Wakabayashi M, Gohda T, Funabiki K, Maeda K, Horikoshi S, Tomino Y: Glomerular changes in the KK-Ay/Ta mouse: A possible model for human type 2 diabetic nephropathy. Nephrology (Carlton) 2006;11:29-35
77. Aoki T, Kaneko S, Tanimoto M, Gohda T, Hagiwara S, Murakoshi M, Ishikawa Y, Furukawa M, Funabiki K, Horikoshi S, Tomino Y: Identification of quantitative trait loci for diabetic nephropathy in KK-Ay/Ta mice. J Nephrol 2012;25:127-136
78. Mooyaart AL: Genetic associations in diabetic nephropathy. Clin Exp Nephrol 2014;18:197-200
79. Macedo CS, Lerco MM, Capelletti SM, Silva RJ, Pinheiro Dde O, Spadella CT: Reduction of podocytes number in late diabetic alloxan nephropathy: Prevention by glycemic control. Acta Cir Bras 2007;22:337-341
80. Ishikwa Y, Ito T, Tanimoto M, Hagiwara S, Furukawa M, Yamaguchi S, Omote K, Asanuma K, Gohda T, Shimizu Y, Funabiki K, Horikoshi S, Tomino Y: Podocyte loss and albuminuria of KK-Ay mouse: A spontaneous animal model for human type 2 diabetic nephropathy. J Diab Mellitus 2012;2:346-352
81. Gu L, Hagiwara S, Fan Q, Tanimoto M, Kobata M, Yamashita M, Nishitani T, Gohda T, Ni Z, Qian J, Horikoshi S, Tomino Y: Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol Dial Transplant 2006;21:299-313
82. Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Ebihara I, Koide H: Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant 2000;15:1379-1383
83. Boor P, Celec P, Behuliak M, Grancic P, Kebis A, Kukan M, Pronayova N, Liptaj T, Ostendorf T, Sebekova K: Regular moderate exercise reduces advanced glycation and ameliorates early diabetic nephropathy in obese Zucker rats. Metabolism 2009;58:1669-1677
84. Ishikawa Y, Gohda T, Tanimoto M, Omote K, Furukawa M, Yamaguchi S, Murakoshi M, Hagiwara S, Horikoshi S, Funabiki K, Tomino Y: Effect of exercise on kidney function, oxidative stress, and inflammation in type 2 diabetic KK-A(y) mice. Exp Diabetes Res 2012;2012:702948
85. Khalifah RG, Baynes JW, Hudson BG: Amadorins: Novel post-Amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun 1999;257:251-258
86. Degenhardt TP, Alderson NL, Arrington DD, Beattie RJ, Basgen JM, Steffes MW, Thorpe SR, Baynes JW: Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002;61:939-950
87. Tanimoto M, Gohda T, Kaneko S, Hagiwara S, Murakoshi M, Aoki T, Yamada K, Ito T, Matsumoto M, Horikoshi S, Tomino Y: Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice. Metabolism 2007;56:160-167
88. Murakoshi M, Tanimoto M, Gohda T, Hagiwara S, Ohara I, Toyoda H, Ishikawa Y, Horikoshi S, Tomino Y: Pleiotropic effect of pyridoxamine on diabetic complications via CD36 expression in KK-Ay/Ta mice. Diabetes Res Clin Pract 2009;83:183-189
89. Chen HC, Guh JY, Shin SJ, Tomino Y, Lai YH: Effects of pravastatin on superoxide and fibronectin production of mesangial cells induced by low-density lipoprotein. Kidney Blood Press Res 2002;25:2-6
90. Gu L, Ni Z, Qian J, Tomino Y: Pravastatin inhibits carboxymethyllysine-induced monocyte chemoattractant protein 1 expression in podocytes via prevention of signalling events. Nephron Exp Nephrol 2007;106:e1-10
91. Matsumoto M, Tanimoto M, Gohda T, Aoki T, Murakoshi M, Yamada K, Yamazaki T, Kaneko S, Horikoshi S, Tomino Y: Effect of pitavastatin on type 2 diabetes mellitus nephropathy in KK-Ay/Ta mice. Metabolism 2008;57:691-697
92. Kimura K, Shimano H, Yokote K, Urashima M, Teramoto T: Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease. Sub-Analysis of the LIVALO Effectiveness and Safety (LIVES) Study. J Atheroscler Thromb 2010;17:601-609
93. Kimura S, Inoguchi T, Yokomizo H, Maeda Y, Sonoda N, Takayanagi R: Randomized comparison of pitavastatin and pravastatin treatment on the reduction of urinary albumin in patients with type 2 diabetic nephropathy. Diabetes Obes Metab 2012;14:666-669
94. Zhang M, Hagiwara S, Matsumoto M, Gu L, Tanimoto M, Nakamura S, Kaneko S, Gohda T, Qian J, Horikoshi S, Tomino Y: Effects of eicosapentaenoic acid on the early stage of type 2 diabetic nephropathy in KKA(y)/Ta mice: Involvement of anti-inflammation and antioxidative stress. Metabolism 2006;55:1590-1598
95. Hagiwara S, Makita Y, Gu L, Tanimoto M, Zhang M, Nakamura S, Kaneko S, Itoh T, Gohda T, Horikoshi S, Tomino Y: Eicosapentaenoic acid ameliorates diabetic nephropathy of type 2 diabetic KKAy/Ta mice: Involvement of MCP-1 suppression and decreased ERK1/2 and p38 phosphorylation. Nephrol Dial Transplant 2006;21:605-615
96. Shimizu H, Ohtani K, Tanaka Y, Sato N, Mori M, Shimomura Y: Long-term effect of eicosapentaenoic acid ethyl (EPA-E) on albuminuria of non-insulin dependent diabetic patients. Diabetes Res Clin Pract 1995;28:35-40
97. Fan Q, Liao J, Kobayashi M, Yamashita M, Gu L, Gohda T, Suzuki Y, Wang LN, Horikoshi S, Tomino Y: Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Nephrol Dial Transplant 2004;19:3012-3020
98. Yamazaki T, Tanimoto M, Gohda T, Ohara I, Hagiwara S, Murakoshi M, Matsumoto M, Kaneko S, Aoki T, Toyoda H, Ishikawa Y, Funabiki K, Horikoshi S, Tomino Y: Combination effects of enalapril and losartan on lipid peroxidation in the kidneys of KK-Ay/Ta mice. Nephron Exp Nephrol 2009;113:e66-76
99. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O'Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P, Investigators VN-D: Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013;369:1892-1903
100. Furukawa M, Gohda T, Hagiwara S, Tanimoto M, Horikoshi S, Funabiki K, Tomino Y: Effect of the direct renin inhibitor aliskiren on urinary albumin excretion in spontaneous type 2 diabetic KK-A (y) mouse. Int J Nephrol 2013;2013:519130
101. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK, Investigators AS: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-2446
102. Benter IF, Yousif MH, Cojocel C, Al-Maghrebi M, Diz DI: Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Am J Physiol Heart Circ Physiol 2007;292:H666-672
103. Brosnihan KB, Li P, Ferrario CM: Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 1996;27:523-528
104. Moon JY, Tanimoto M, Gohda T, Hagiwara S, Yamazaki T, Ohara I, Murakoshi M, Aoki T, Ishikawa Y, Lee SH, Jeong KH, Lee TW, Ihm CG, Lim SJ, Tomino Y: Attenuating effect of angiotensin-(1-7) on angiotensin IImediated NAD(P)H oxidase activation in type 2 diabetic nephropathy of KK-A(y)/Ta mice. Am J Physiol Renal Physiol 2011;300:F1271-1282
105. Ohara I, Tanimoto M, Gohda T, Yamazaki T, Hagiwara S, Murakoshi M, Aoki T, Toyoda H, Ishikawa Y, Funabiki K, Horikoshi S, Tomino Y: Effect of combination therapy with angiotensin receptor blocker and 1,25-dihydroxyvitamin D(3) in type 2 diabetic nephropathy in KK-A(y)/Ta mice. Nephron Exp Nephrol 2011;117:e124-132
106. Hamada C, Tomino Y: Histological alterations in peritonela dialysis. Juntendo Med J 2014, in press
107. Kaneko K, Hamada C, Tomino Y: Peritoneal fibrosis intervention. Perit Dial Int 2007;27:S82-86
108. Io H, Hamada C, Ro Y, Ito Y, Hirahara I, Tomino Y: Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int 2004;65:1927-1936
109. Ro Y, Hamada C, Io H, Hayashi K, Hirahara I, Tomino Y: Rapid, simple, and reliable method for the diagnosis of CAPD peritonitis using the new MMP-9 test kit. J Clin Lab Anal 2004;18:224-230
110. Kanda R, Hamada C, Kaneko K, Nakano T, Wakabayashi K, Io H, Horikoshi S, Tomino Y: Pentraxin 3 as a new biomarker of peritoneal injury in peritoneal dialysis patients. J Artif Organs 2013;16:66-73
111. Di Paolo N, Sacchi G, De Mia M, Gaggiotti E, Capotondo L, Rossi P, Bernini M, Pucci AM, Ibba L, Sabatelli P, et al.: Morphology of the peritoneal membrane during continuous ambulatory peritoneal dialysis. Nephron 1986;44:204-211
112. Dobbie JW, Lloyd JK, Gall CA: Categorization of ultrastructural changes in peritoneal mesothelium, stroma and blood vessels in uremia and CAPD patients. Adv Perit Dial 1990;6:3-12
113. Twardowski ZJ: Clinical value of standardized equilibration tests in CAPD patients. Current Concepts of CAPD. Blood Purif 1989;7:95-108
114. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, Mackenzie RK, Williams GT, Peritoneal Biopsy Study G: Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002;13:470-479
115. Honda K, Hamada C, Nakayama M, Miyazaki M, Sherif AM, Harada T, Hirano H, Peritoneal Biopsy Study Group of the Japanese Society for Peritoneal D: Impact of uremia, diabetes, and peritoneal dialysis itself on the pathogenesis of peritoneal sclerosis: A quantitative study of peritoneal membrane morphology. Clin J Am Soc Nephrol 2008;3:720-728
116. Shimaoka T, Hamada C, Kaneko K, Io H, Sekiguchi Y, Aruga S, Inuma J, Inami Y, Hotta Y, Horikoshi S, Kumasaka T, Tomino Y: Quantitative evaluation and assessment of peritoneal morphologic changes in peritoneal dialysis patients. Nephrol Dial Transplant 2010;25:3379-3385
117. Yokoyama K, Yoshida H, Matsuo N, Maruyama Y, Kawamura Y, Yamamoto R, Hanaoka K, Ikeda M, Yamamoto H, Nakayama M, Kawaguchi Y, Hosoya T: Serum beta2 microglobulin (beta2 MG) level is a potential predictor for encapsulating peritoneal sclerosis (EPS) in peritoneal dialysis patients. Clin Nephrol 2008;69:121-126
118. Nakamoto H, Hamada C, Shimaoka T, Sekiguchi Y, Io H, Kaneko K, Horikoshi S, Tomino Y: Accumulation of advanced glycation end products and beta 2-microglobulin in fibrotic thickening of the peritoneum in longterm peritoneal dialysis patients. J Artif Organs 2014;17:60-68
119. Osada S, Hamada C, Shimaoka T, Kaneko K, Horikoshi S, Tomino Y: Alterations in proteoglycan components and histopathology of the peritoneum in uraemic and peritoneal dialysis (PD) patients. Nephrol Dial Transplant 2009;24:3504-3512
120. Nakazato Y, Yamaji Y, Oshima N, Hayashi M, Saruta T: Calcification and osteopontin localization in the peritoneum of patients on long-term continuous ambulatory peritoneal dialysis therapy. Nephrol Dial Transplant 2002;17:1293-1303
121. Braun N, Alscher MD, Fritz P, Latus J, Edenhofer I, Reimold F, Alper SL, Kimmel M, Biegger D, Lindenmeyer M, Cohen CD, Wuthrich RP, Segerer S: The spectrum of podoplanin expression in encapsulating peritoneal sclerosis. PLoS One 2012;7:e53382
122. Ro Y, Hamada C, Inaba M, Io H, Kaneko K, Tomino Y: Inhibitory effects of matrix metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats. Nephrol Dial Transplant 2007;22:2838-2848
123. Matsumoto M, Io H, Furukawa M, Okumura K, Masuda A, Seto T, Takagi M, Sato M, Nagahama L, Omote K, Hisada A, Horikoshi S, Tomino Y: Risk factors associated with increased left ventricular mass index in chronic kidney disease patients evaluated using echocardiography. J Nephrol 2012;25:794-801
124. Io H, Ro Y, Sekiguchi Y, Shimaoka T, Inuma J, Hotta Y, Aruga S, Inami Y, Sato M, Kobayashi T, Masuda A, Kaneko K, Hamada C, Ohtaki E, Horikoshi S, Tomino Y: Cardiac function and structure in longitudinal analysis of echocardiography in peritoneal dialysis patients. Perit Dial Int 2010;30:353-361
125. Ishii M, Ohsawa I, Inoshita H, Kusaba G, Onda K, Wakabayashi M, Ohi H, Horikoshi S, Matsushita M, Tomino Y: Serum concentration of complement components of the lectin pathway in maintenance hemodialysis patients, and relatively higher levels of L-Ficolin and MASP-2 in Mannose-binding lectin deficiency. Ther Apher Dial 2011;15:441-447
126. Klein NJ: Mannose-binding lectin: Do we need it? Mol Immunol 2005;42:919-924
127. Thiel S, Frederiksen PD, Jensenius JC: Clinical manifestations of mannan-binding lectin deficiency. Mol Immunol 2006;43:86-96
128. Sorensen R, Thiel S, Jensenius JC: Mannan-binding-lectin-Associated serine proteases, characteristics and disease associations. Springer Semin Immunopathol 2005;27:299-319
129. Dahl M, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG: A population-based study of morbidity and mortality in mannose-binding lectin deficiency. J Exp Med 2004;199:1391-1399
130. Atkinson AP, Cedzynski M, Szemraj J, St Swierzko A, Bak-Romaniszyn L, Banasik M, Zeman K, Matsushita M, Turner ML, Kilpatrick DC: L-ficolin in children with recurrent respiratory infections. Clin Exp Immunol 2004;138:517-520
131. Inoshita H, Ohsawa I, Kusaba G, Ishii M, Onda K, Horikoshi S, Ohi H, Tomino Y: Complement in patients receiving maintenance hemodialysis: Functional screening and quantitative analysis. BMC Nephrol 2010;11:34
132. Shimizu Y, Sonoda A, Nogi C, Ogushi Y, Kanda R, Yamaguchi S, Nohara N, Aoki T, Yamada K, Nakata J, Io H, Kurusu A, Hamada C, Horikoshi S, Tomino Y: B-type (brain) natriuretic peptide and pruritus in hemodialysis patients. Int J Nephrol Renovasc Dis 2014;7:329-335
133. Io H, Matsumoto M, Okumura K, Sato M, Masuda A, Furukawa M, Nohara N, Tanimoto M, Kodama F, Hagiwara S, Gohda T, Shimizu Y, Tomino Y: Predictive factors associated with left ventricular hypertrophy at baseline and in the follow-up period in non-diabetic hemodialysis patients. Semin Dial 2011;24:349-354
134. Furukawa M, Io H, Tanimoto M, Hagiwara S, Horikoshi S, Tomino Y: Predictive factors associated with the period of time before initiation of hemodialysis in CKD stages 4 and 5. Nephron Clin Pract 2011;117:c341-347
135. Nakatani T, Naganuma T, Masuda C, Sugimura T, Uchida J, Takemoto Y, Sugimura K: The prognostic role of atrial natriuretic peptides in hemodialysis patients. Blood Purif 2003;21:395-400
136. Tsang TS, Barnes ME, Gersh BJ, Takemoto Y, Rosales AG, Bailey KR, Seward JB: Prediction of risk for first age-related cardiovascular events in an elderly population: The incremental value of echocardiography. J Am Coll Cardiol 2003;42:1199-1205
137. Foley RN, Parfrey PS, Morgan J, Barre PE, Campbell P, Cartier P, Coyle D, Fine A, Handa P, Kingma I, Lau CY, Levin A, Mendelssohn D, Muirhead N, Murphy B, Plante RK, Posen G, Wells GA: Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000;58:1325-1335
138. Jeren-Struji'c B, Raos V, Jeren T, Horvatin-Godler S: Morphologic and functional changes of left ventricle in dialyzed patients after treatment with recombinant human erythropoietin (r-HuEPO). Angiology 2000;51:131-139
139. Levin A, Djurdjev O, Barrett B, Burgess E, Carlisle E, Ethier J, Jindal K, Mendelssohn D, Tobe S, Singer J, Thompson C: Cardiovascular disease in patients with chronic kidney disease: Getting to the heart of the matter. Am J Kidney Dis 2001;38:1398-1407
140. Huting J, Kramer W, Schutterle G, Wizemann V: Analysis of left-ventricular changes associated with chronic hemodialysis. A noninvasive follow-up study. Nephron 1988;49:284-290
141. Laukkanen JA, Kurl S, Eranen J, Huttunen M, Salonen JT: Left atrium size and the risk of cardiovascular death in middle-Aged men. Arch Intern Med 2005;165:1788-1793
142. Chan CT, Floras JS, Miller JA, Richardson RM, Pierratos A: Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int 2002;61:2235-2239
143. Chan CT, Harvey PJ, Picton P, Pierratos A, Miller JA, Floras JS: Short-term blood pressure, noradrenergic, and vascular effects of nocturnal home hemodialysis. Hypertension 2003;42:925-931
144. Nagano M, Higaki J, Mikami H, Nakamaru M, Higashimori K, Katahira K, Tabuchi Y, Moriguchi A, Nakamura F, Ogihara T: Converting enzyme inhibitors regressed cardiac hypertrophy and reduced tissue angiotensin II in spontaneously hypertensive rats. J Hypertens 1991;9:595-599